These results hint that the tubulointerstitial anti-inflammatory and antifibrotic actions of ALLO in the Nx model engage suppression of the NLRP3 pathway and bolster the belief that ALLO can arrest or impede the progression of CKD. Here, NLRP3 is linked to chronic kidney disease.